FHTX · Foghorn Therapeutics Inc
United States · RS rating 3 · As of 2026-10-14
| Price | 1.85 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 3 / 2 / 3 / 12 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 3 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +65.5% |
| Sales growth Q/Q | +13.4% |
| Distance from 52-week high | +73.8% |
| Market cap (USD) | $304.7M |